GlaxoSmithKline Subsidiary Gets Positive Opinion for HIV Drug
26 Abril 2019 - 11:00AM
Noticias Dow Jones
By Oliver Griffin
GlaxoSmithKline PLC (GSK.LN) Friday said its majority-owned ViiV
Healthcare has received a positive opinion from European medical
authorities for its Dovato HIV treatment.
The pharmaceutical company said that ViiV--which also counts
Pfizer Inc. (PFE) and Shionogi & Co. Ltd. (4507.TO) as
shareholders--received a positive opinion from the Committee for
Medicinal Products for Human Use, recommending marketing
authorization for Dovato.
The committee, which is part of the European Medicines Agency,
issued the opinion based on landmark studies, GlaxoSmithKline
said.
Dovato is for the treatment of HIV-1 infection in adults and
adolescents above 12 years of age, the company said.
An opinion from the Committee for Medicinal Products for Human
Use is one of the final steps before a marketing authorization
decision is made by the European Commission, the company said.
Write to Oliver Griffin at oliver.griffin@dowjones.com;
@OliGGriffin
(END) Dow Jones Newswires
April 26, 2019 11:45 ET (15:45 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024